Long-term outcomes of colorectal cancer patients with and without malignant large-bowel obstruction | Zendy

Shinya Munakata | Zendy; Yuta Murai | Zendy; Akihiro Koiuzumi | Zendy; Hisaki Kato | Zendy; Riku Yamamoto | Zendy; Shuhei Ueda | Zendy; Satoshi Tokuda | Zendy; Shunsuke Sakuraba | Zendy; Tomoyuki Kushida | Zendy; Hajime Orita | Zendy; Mutsumi Sakurada | Zendy; Hiroshi Maekawa | Zendy; Koichi Sato | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Long-term outcomes of colorectal cancer patients with and without malignant large-bowel obstruction

Author(s) -

Shinya Munakata,

Yuta Murai,

Akihiro Koiuzumi,

Hisaki Kato,

Riku Yamamoto,

Shuhei Ueda,

Satoshi Tokuda,

Shunsuke Sakuraba,

Tomoyuki Kushida,

Hajime Orita,

Mutsumi Sakurada,

Hiroshi Maekawa,

Koichi Sato

Publication year - 2018

Publication title -

colorectal cancer

Language(s) - English

Resource type - Journals

eISSN - 1758-1958

pISSN - 1758-194X

DOI - 10.2217/crc-2018-0001

Subject(s) - medicine , colorectal cancer , stage (stratigraphy) , bowel obstruction , cancer , oncology , adjuvant chemotherapy , overall survival , gastroenterology , disease , surgery , chemotherapy , survival rate , paleontology , breast cancer , biology

Aim: Colorectal cancer patients with malignant large-bowel obstruction (MLBO) require emergency treatment. Here we evaluated the long-term outcomes of recurrence and prognosis (not short-term mortality or nonocclusive cancer T1–T2) in colorectal cancer patients with and without an MLBO. Methods: We retrospectively analyzed the cases of the consecutive patients who underwent curative resection for colon cancer. We compared the groups regarding patients’ age and gender, the tumor location, T and N factor, tumor stage, disease-free survival and overall survival. Results: The nonobstruction group had a significantly longer disease-free survival and overall survival compared with the MLBO group. Conclusion: MLBO was associated with cancer recurrence and poorer overall survival regardless of the staging and adjuvant chemotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research